Moving toward the ideal insulin for insulin pumps
Abstract
Advances in insulin formulations have been important for diabetes management and achieving optimal glycemic control. Rapid-acting insulin analogs provide a faster time-action profile than regular insulin and are approved for use in pumps. However, the need remains for therapy to deliver a more physiologic insulin profile. New insulin formulations and delivery methods are in development, with the aim of accelerating insulin absorption to accomplish ultra-fast-acting insulin time-action profiles. Furthermore, the integration of continuous glucose monitoring with insulin pump therapy enables on-going adjustment of insulin delivery to optimize glycemic control throughout the day and night. These technological and pharmacological advances are likely to facilitate the development of closed-loop pump systems (i.e., artificial pancreas), and improve glycemic control and quality of life for patients with diabetes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Insulin action can be delayed and vary between individuals and with different insulin analogues, which limits the ability of the AID system to respond promptly to rising glucose concentrations.
“Insulin action can be delayed and vary between individuals and with different insulin analogues, which limits the ability of the AID system to respond promptly to rising glucose concentrations.105”
From The future of type 1 diabetes therapy (2025) · cites this paper as [105]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 94 · Cited by 38
- Authors
- Cengiz, E., Bode, B., Van Name, M., & Tamborlane, W. V.
- Affiliations
- Yale University (US)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Cengiz, Eda
- Venue
- Expert Review of Medical Devices
- Publisher
- Informa UK Limited
- Published
- 2015-11-11
- Volume
- 13
- Issue
- 1
- Pages
- 57-69
- ISSN
- 1743-4440 (ISSN-L)
- 1745-2422
- OpenAlex
- W2221738370
- Cited by
- 38
- References
- 94
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Medical Devices (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- insulin pump, insulin formulations, rapid-acting insulin analogs, insulin absorption, continuous glucose monitoring, artificial pancreas, glycemic control, diabetes management
- MeSH terms
- Amino Acid Sequence, Humans, Insulin, Insulin Infusion Systems, Molecular Sequence Data, Insulin, Short-Acting, Absorption, Physiological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
